Department of Health and Human Services, through National Institutes of Health, awarded Microbiotix, Inc. of Worcester, MA $599,327 under the STTR program (Phase I), with work starting 2025-09-22 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Microbiotix, Inc. received in the last two years, $1,187,227 in all. Each figure links to the federal record.
The award
| Recipient | Microbiotix, Inc. (Worcester, MA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $599,327 |
| Period of performance starts | 2025-09-22 |
| Period of performance ends | 2027-08-31 |
| Award number | R41AI195240 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Worcester, Worcester County, MA |
| Signed | 2025-09-20 |
| Recipient registry id (UEI) | SCNKBDM341T1 |
Want the whole picture on Microbiotix, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Microbiotix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Microbiotix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections - title: Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections abstract. The fungal order mucorales [a who
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-25 | Continuation | 000 | $299,381 |
| 2025-09-20 | New | 000 | $299,946 |
Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections - title: Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections abstract. The fungal order mucorales [a who “high priority group” fungal pathogen] are the causative agents of mucormycosis, an aggressive, opportunistic mould infection that has devasting outcomes, with an overall mortality rate of ~50-60%. Mucormycosis primarily afflicts immunosuppressed patients. The progression of the disease is rapid. Once the infection has disseminated, IT is almost always fatal. Treatment options for mucormycosis are severely limited, as these fungi are intrinsically resistant to contemporary antifungals, including the echinocandins and most of the azoles. The antifungal agents in the development pipeline exhibit poor or no activity against mucorales, making the development of new, potent, and safe antifungals against mucorales remains an urgent, unmet need. To address this need, we identified a novel series of benzyl-piperidines (bps) that exhibit potent antifungal activity against pathogenic moulds. A representative bp, MBX-7591, exhibited potent antifungal activity against representative pathogens of the mucorales, such as rhizopus delemar and mucor lusitanicus, in in vitro susceptibility assays and in a murine model of acute invasive pulmonary mucormycosis. Based on these exci ...
From the federal award record.
Other SBIR and STTR awards to Microbiotix, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-08 | Department of Health and Human Services | SBIR Phase I | $587,900 | Development of well tolerated novel inhibitors of drug resistant cmv - cmv occurs as a ben (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Microbiotix, Inc.Look up Microbiotix, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.